CoChat

Comprehensive review of targeted therapy for colorectal cancer

Open access
Xie, Yuan-Hong, Chen, Ying-Xuan, Fang, Jing-Yuan · 2020 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 521 of the 521 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have long been the first choices for cancer patients. However, the prognosis of CRC has never been satisfying, especially for patients with metastatic lesions. Targeted therapy is a new optional approach that has successfully prolonged overall survival for CRC patients. Following successes with the anti-EGFR (epidermal growth factor receptor) agent cetuximab and the anti-angiogenesis agent bevacizumab, new agents blocking different critical pathways as well as immune checkpoints are emerging at an unprecedented rate. Guidelines worldwide are currently updating the recommended targeted drugs on the basis of the increasing number of high-quality clinical trials. This review provides an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-0116-z

Cites

521 of 521 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 United States of America Food and Drug Administration (FDA)-approved targeted agents in colorectal cancer. VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor
Fig. 1 United States of America Food and Drug Administration (FDA)-approved targeted agents in colorectal cancer. VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptorCC BY · PubMed Central
Fig. 2 Pathways offering potential sites for targeted therapy. CRC: colorectal cancer; VEGF/VEGFR: vascular endothelial growth factor/vascular endothelial growth factor receptor; EGF/EGFR: epidermal growth factor/epidermal growth factor receptor; HGF: hepatocyte growth factor; c-MET: mesenchymal–epithelial transition factor; IGF/IGF-1R: insulin-like growth factor/ insulin-like growth factor 1 receptor; TGF: transforming growth factor
Fig. 2 Pathways offering potential sites for targeted therapy. CRC: colorectal cancer; VEGF/VEGFR: vascular endothelial growth factor/vascular endothelial growth factor receptor; EGF/EGFR: epidermal growth factor/epidermal growth factor receptor; HGF: hepatocyte growth factor; c-MET: mesenchymal–epithelial transition factor; IGF/IGF-1R: insulin-like growth factor/ insulin-like growth factor 1 receptor; TGF: transforming growth factorCC BY · PubMed Central
Fig. 3 Overview of National Comprehensive Cancer Network (NCCN)-recommended targeted agents. HGF: hepatocyte growth factor; c-MET: mesenchymal–epithelial transition factor; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor; EGF: epidermal growth factor; HER2: human epidermal growth factor 2; CTLA-4: cytotoxic T lymphocyte-associated antigen 4; PD-1: programmed death-1; PD-L1: programmed death ligand 1; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B, also known as PKB; mTOR: mammalian target of rapamycin; MEK: mitogen-activated protein kinase; ERK: extracellular signal-regulated kinase. *These agents have not been recommended by the NCCN. **This agent has been approved by the National Medical Products Administration of China (NMPA), but not by the United States of America Food and Drug Administration (FDA)
Fig. 3 Overview of National Comprehensive Cancer Network (NCCN)-recommended targeted agents. HGF: hepatocyte growth factor; c-MET: mesenchymal–epithelial transition factor; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor; EGF: epidermal growth factor; HER2: human epidermal growth factor 2; CTLA-4: cytotoxic T lymphocyte-associated antigen 4; PD-1: programmed death-1; PD-L1: programmed death ligand 1; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B, also known as PKB; mTOR: mammalian target of rapamycin; MEK: mitogen-activated protein kinase; ERK: extracellular signal-regulated kinase. *These agents have not been recommended by the NCCN. **This agent has been approved by the National Medical Products Administration of China (NMPA), but not by the United States of America Food and Drug Administration (FDA)CC BY · PubMed Central
Fig. 4 National Comprehensive Cancer Network (NCCN)-recommended strategy for metastatic colorectal cancer targeted therapy. mCRC: metastatic colorectal cancer; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial growth factor; PD-1/L1: programmed death-1/programmed death ligand 1; dMMR: deficient mismatch repair; pMMR: proficient mismatch repair; HER2: human epidermal growth factor 2; BSC: best supportive care; WT: wild type; mut: mutated; amp: amplified. *The NCCN recommends initial administration of PD-1/PD-L1 therapy only in patients in poor functional status
Fig. 4 National Comprehensive Cancer Network (NCCN)-recommended strategy for metastatic colorectal cancer targeted therapy. mCRC: metastatic colorectal cancer; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial growth factor; PD-1/L1: programmed death-1/programmed death ligand 1; dMMR: deficient mismatch repair; pMMR: proficient mismatch repair; HER2: human epidermal growth factor 2; BSC: best supportive care; WT: wild type; mut: mutated; amp: amplified. *The NCCN recommends initial administration of PD-1/PD-L1 therapy only in patients in poor functional statusCC BY · PubMed Central
Fig. 5 Crosstalk and bypass mechanisms between pathways. VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor; c-MET: mesenchymal–epithelial transition factor; IGF-1R: insulin-like growth factor 1 receptor; TGF-β: transforming growth factor-β; RON-R: recepteur d’Origine nantais; PDGFR: platelet-derived growth factor receptor; *with multiple isoforms
Fig. 5 Crosstalk and bypass mechanisms between pathways. VEGFR: vascular endothelial growth factor receptor; EGFR: epidermal growth factor receptor; c-MET: mesenchymal–epithelial transition factor; IGF-1R: insulin-like growth factor 1 receptor; TGF-β: transforming growth factor-β; RON-R: recepteur d’Origine nantais; PDGFR: platelet-derived growth factor receptor; *with multiple isoformsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 521 references

Cited by

See all 1,687

Metadata

Authors
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
Fang, Jing-Yuan
Venue
Signal Transduction and Targeted Therapy
Published
2020-03-20
Volume
5
Issue
1
Pages
22-22
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3011481749
Cited by
1,687
References
521
Citations by year
2026: 153 · 2025: 285 · 2024: 348 · 2023: 346 · 2022: 300 · 2021: 202 · 2020: 51
FWCI
24.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81421001, 81530072)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
colorectal cancer, targeted therapy, metastatic colorectal cancer, anti-EGFR therapy, cetuximab, bevacizumab, angiogenesis inhibitors, immune checkpoint inhibitors, molecular pathways, drug mechanisms, treatment guidelines
MeSH terms
Bevacizumab, Cetuximab, Humans, Neoplasm Metastasis, Neovascularization, Pathologic, Colorectal Neoplasms, Molecular Targeted Therapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive review of targeted therapy for colorectal cancer. https://app.cochat.ai/papers/10.1038/s41392-020-0116-z
The paper
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020). Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-0116-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.